Risperidone | CAS#106266-06-2 | 5-HT Receptor Inhibitor

MedKoo Cat#: 318669 | Name: Risperidone

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Risperidone is an antipsychotic medication. It is mainly used as a long lasting injection to treat schizophrenia, bipolar disorder, and irritability in people with autism. It is taken either by mouth or by injection into a muscle.

Chemical Structure

Risperidone

CAS#106266-06-2 (free base)

Theoretical Analysis

MedKoo Cat#: 318669

Name: Risperidone

CAS#: 106266-06-2 (free base)

Chemical Formula: C23H27FN4O2

Exact Mass: 410.2118

Molecular Weight: 410.48

Elemental Analysis: C, 67.30; H, 6.63; F, 4.63; N, 13.65; O, 7.80

Price and Availability

Size	Price	Availability
50mg	USD 150.00	Ready to ship
100mg	USD 200.00	Ready to ship
200mg	USD 300.00	Ready to ship
500mg	USD 550.00	Ready to ship
1g	USD 850.00	Ready to ship
2g	USD 1,350.00	Ready to ship

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

666179-96-0 (mesylate) 106266-06-2 (free base)

Synonym

Risperidone, Risperidal, R 64766; R-64766, R64766

IUPAC/Chemical Name

3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one

InChi Key

RAPZEAPATHNIPO-UHFFFAOYSA-N

InChi Code

InChI=1S/C23H27FN4O2/c1-15-18(23(29)28-10-3-2-4-21(28)25-15)9-13-27-11-7-16(8-12-27)22-19-6-5-17(24)14-20(19)30-26-22/h5-6,14,16H,2-4,7-13H2,1H3

SMILES Code

O=C1C(CCN2CCC(C3=NOC4=CC(F)=CC=C34)CC2)=C(C)N=C5N1CCCC5

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Certificate of Analysis

View CoA: current batch, Lot#A22M07B15

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Biological target:

Risperidone is a serotonin 5-HT2 receptor blocker, P-Glycoprotein inhibitor and potent dopamine D2 receptor antagonist, with Kis of 4.8, 5.9 nM for 5-HT2A and dopamine D2 receptor, respectively.

In vitro activity:

In addition, individual treatment with Risperidone brought about promotion of OPG mRNA and protein expression and inhibition of collagen I and RANKL mRNA and protein expression levels, the effect of which was abolished by additional TNF-α silencing. Meanwhile, additional SATB2 silencing also induced the promotion of OPG expression and inhibition of collagen I and RANKL expression levels in the Risperidone-treated TNF-α-deficient MC3T3-E1 cells (Fig. 5A, B, Additional file 1: Fig. S1A). Reference: Mol Med. 2022 May 3;28(1):46. https://pubmed.ncbi.nlm.nih.gov/35505281/

In vivo activity:

In contrast, in risperidone-treated rats, the immunoreactivity of the pro-inflammatory cytokines was significantly decreased, and the anti-inflammatory cytokines were enhanced compared to vehicle-treated rats. In brief, risperidone treatment after ACA/CPR (asphyxia CA and cardiopulmonary resuscitation) in rats significantly improved the survival rate and attenuated paralysis, the damage/death (loss) of motor neurons, and inflammation in the lumbar anterior horn. Thus, risperidone might be a therapeutic agent for paraplegia by attenuation of the damage/death (loss) of spinal motor neurons and neuroinflammation after ACA/CPR. Reference: Vet Sci. 2021 Oct 13;8(10):230. https://pubmed.ncbi.nlm.nih.gov/34679060/

	Solvent	mg/mL	mM
Solubility
	DMF	0.1	0.24
	DMF:PBS (pH 7.2) (1:1)	0.5	1.22
	DMSO	4.8	11.63
	Ethanol	2.8	6.82

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 410.48 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Zhang S, He W, Li A, Zhao C, Chen Y, Xu C, Zhang Q, Zheng D, Chen M, Miao H, Huang Y. Involvement of the TNF-α/SATB2 axis in the induced apoptosis and inhibited autophagy of osteoblasts by the antipsychotic Risperidone. Mol Med. 2022 May 3;28(1):46. doi: 10.1186/s10020-022-00466-9. PMID: 35505281; PMCID: PMC9066868. 2. Canfrán-Duque A, Pastor Ó, García-Seisdedos D, Molina YL, Babiy B, Lerma M, Sánchez-Castellano C, Martínez-Botas J, Gómez-Coronado D, Lasunción MA, Cruz-Jentoft AJ, Busto R. The Antipsychotic Risperidone Alters Dihydroceramide and Ceramide Composition and Plasma Membrane Function in Leukocytes In Vitro and In Vivo. Int J Mol Sci. 2021 Apr 10;22(8):3919. doi: 10.3390/ijms22083919. PMID: 33920193; PMCID: PMC8069118. 3. Rami FZ, Nguyen TB, Oh YE, Karamikheirabad M, Le TH, Chung YC. Risperidone Induced DNA Methylation Changes in Dopamine Receptor and Stathmin Genes in Mice Exposed to Social Defeat Stress. Clin Psychopharmacol Neurosci. 2022 May 31;20(2):373-388. doi: 10.9758/cpn.2022.20.2.373. PMID: 35466108; PMCID: PMC9048015. 4. Lee TK, Lee JC, Tae HJ, Kim HI, Shin MC, Ahn JH, Park JH, Kim DW, Hong S, Choi SY, Cho JH, Won MH. Therapeutic Effects of Risperidone against Spinal Cord Injury in a Rat Model of Asphyxial Cardiac Arrest: A Focus on Body Temperature, Paraplegia, Motor Neuron Damage, and Neuroinflammation. Vet Sci. 2021 Oct 13;8(10):230. doi: 10.3390/vetsci8100230. PMID: 34679060; PMCID: PMC8537088.

In vitro protocol:

In vivo protocol:

1. Rami FZ, Nguyen TB, Oh YE, Karamikheirabad M, Le TH, Chung YC. Risperidone Induced DNA Methylation Changes in Dopamine Receptor and Stathmin Genes in Mice Exposed to Social Defeat Stress. Clin Psychopharmacol Neurosci. 2022 May 31;20(2):373-388. doi: 10.9758/cpn.2022.20.2.373. PMID: 35466108; PMCID: PMC9048015. 2. Lee TK, Lee JC, Tae HJ, Kim HI, Shin MC, Ahn JH, Park JH, Kim DW, Hong S, Choi SY, Cho JH, Won MH. Therapeutic Effects of Risperidone against Spinal Cord Injury in a Rat Model of Asphyxial Cardiac Arrest: A Focus on Body Temperature, Paraplegia, Motor Neuron Damage, and Neuroinflammation. Vet Sci. 2021 Oct 13;8(10):230. doi: 10.3390/vetsci8100230. PMID: 34679060; PMCID: PMC8537088.

1: Soto-Sánchez J, Garza-Treviño G. Individualized Homeopathic Treatment for Persistent Insomnia and Generalized Anxiety Disorder: A Case Report. Cureus. 2024 Aug 19;16(8):e67203. doi: 10.7759/cureus.67203. PMID: 39295670; PMCID: PMC11409940. 2: Tazi A, Errachidi F, Sonawane D, Tahri G, Rao S, Mehta S. An economic model to understand the cost-effectiveness of olanzapine orally dispersible tablets (ODT) and olanzapine film coated tablets as a group compared with other oral atypical antipsychotics for treating schizophrenia in Morocco. Ann Gen Psychiatry. 2024 Sep 18;23(1):33. doi: 10.1186/s12991-024-00516-y. PMID: 39294740. 3: Ben-Azu B, Fokoua AR, Annafi OS, Adebayo OG, Del Re EC, Okuchukwu N, Aregbesola GJ, Ejenavi AC, Isiwele DM, Efezino AJ, Okpu ID. Effective action of silymarin against ketamine-induced schizophrenia in male mice: Insight into the biochemical and molecular mechanisms of action. J Psychiatr Res. 2024 Sep 12;179:141-155. doi: 10.1016/j.jpsychires.2024.09.003. Epub ahead of print. PMID: 39293119. 4: De R, Smith ECC, Navagnanavel J, Au E, Maksyutynska K, Papoulias M, Singh R, Panganiban KJ, Humber B, Mohr GH, Nielsen MØ, Ebdrup BH, Remington G, Agarwal SM, Hahn MK. The impact of weight gain on antipsychotic nonadherence or discontinuation: A systematic review and meta-analysis. Acta Psychiatr Scand. 2024 Sep 17. doi: 10.1111/acps.13758. Epub ahead of print. PMID: 39285800. 5: Yang X, Zheng X, Zhang M, Huang J, Huang P, Wang J. Drug-Induced Gynecomastia: Data Mining and Analysis of the FDA Adverse Event Reporting System Database. Clin Epidemiol. 2024 Sep 11;16:617-630. doi: 10.2147/CLEP.S470959. PMID: 39280118; PMCID: PMC11402344. 6: Tamrakar S, Mendoza Diaz A, Nevarez Flores AG, Castle D. Characterising the nature of psychiatric disorders and patterns of antipsychotic medications prescribed in a psychiatric ward in a public hospital in Tasmania. Australas Psychiatry. 2024 Sep 13:10398562241283156. doi: 10.1177/10398562241283156. Epub ahead of print. PMID: 39275805. 7: Yuan R, Li Y, Li X, Fu Y, Ning A, Wang D, Zhang R, Yu S, Xu Q. Transcriptome analysis to explore the mechanism of downregulated TNIK influencing the effect of risperidone. Front Pharmacol. 2024 Aug 23;15:1431923. doi: 10.3389/fphar.2024.1431923. PMID: 39268461; PMCID: PMC11391209. 8: Ueda A, Nohara K, Obara M, Watanabe S. Analysis of anticholinergic drugs associated with aspiration pneumonia using the Japanese adverse drug event report database: Supplementary insights from a scoping review. Respir Investig. 2024 Sep 10;62(6):1044-1050. doi: 10.1016/j.resinv.2024.09.003. Epub ahead of print. PMID: 39260157. 9: Bond Q, Agrawal H. Pharmacological tightrope: risperidone's balancing act in cri du chat syndrome. Discov Ment Health. 2024 Sep 10;4(1):35. doi: 10.1007/s44192-024-00094-1. PMID: 39256321; PMCID: PMC11387558. 10: Lam LK, Poon LY, Xu PL, Xie PC, Xie T, Xiao Y, Chen LG. Efficacy and safety of a Chinese medicine formula Diankuang Mengxing Decoction combined with antipsychotics in the treatment of schizophrenia: A meta-analysis of randomized controlled trials. Medicine (Baltimore). 2024 Sep 6;103(36):e39489. doi: 10.1097/MD.0000000000039489. PMID: 39252273; PMCID: PMC11384066. 11: Liu L, Li Z, Kong D, Huang Y, Wu D, Zhao H, Gao X, Zhang X, Yang M. Neuroimaging markers of aberrant brain activity and treatment response in schizophrenia patients based on brain complexity. Transl Psychiatry. 2024 Sep 9;14(1):365. doi: 10.1038/s41398-024-03067-8. PMID: 39251595; PMCID: PMC11384759. 12: Chen W, Li H, Zhang X, Sang Y, Nie Z. Microfluidic preparation of monodisperse PLGA-PEG/PLGA microspheres with controllable morphology for drug release. Lab Chip. 2024 Sep 9. doi: 10.1039/d4lc00486h. Epub ahead of print. PMID: 39248189. 13: Obeidat A, Al-Moussally F, Abdallah W. Successful Treatment of Risperidone- Induced Hypothermia With Aripiprazole: A Brief Case Report and a Literature Review. Cureus. 2024 Aug 8;16(8):e66464. doi: 10.7759/cureus.66464. PMID: 39246932; PMCID: PMC11380560. 14: Weng J, Zhu X, Ouyang Y, Liu Y, Lu H, Yao J, Pan B. Identification of Immune-Related Biomarkers of Schizophrenia in the Central Nervous System Using Bioinformatic Methods and Machine Learning Algorithms. Mol Neurobiol. 2024 Sep 7. doi: 10.1007/s12035-024-04461-5. Epub ahead of print. PMID: 39243324. 15: Kendricks DR, Morrow C, Haste DA, Newland MC. Adult and adolescent antipsychotic exposure increases delay discounting and diminishes behavioral flexibility in male C57BL/6 mice. Pharmacol Biochem Behav. 2024 Sep 4;245:173866. doi: 10.1016/j.pbb.2024.173866. Epub ahead of print. PMID: 39241867. 16: Alenazi B, Al Doghaither HA, Al-Ghafari AB, Elmorsy EM. Risperidone-induced bioenergetic disruption in the isolated human peripheral blood monocytes. Toxicol In Vitro. 2024 Sep 3;101:105936. doi: 10.1016/j.tiv.2024.105936. Epub ahead of print. PMID: 39237056. 17: D N, D L, B LD, C P, S HB. Echoes of the Mind: Auditory Charles Bonnet Syndrome. Cureus. 2024 Aug 4;16(8):e66120. doi: 10.7759/cureus.66120. PMID: 39229405; PMCID: PMC11370646. 18: Marques D, Vaziri N, Greenway SC, Bousman C. DNA methylation and histone modifications associated with antipsychotic treatment: a systematic review. Mol Psychiatry. 2024 Sep 3. doi: 10.1038/s41380-024-02735-x. Epub ahead of print. PMID: 39227433. 19: De Las Cuevas C, de Leon VC, Blasco-Fontecilla H, Baca-García E, Sagud M, Sanz EJ, de Leon J. Clozapine may consistently protect from suicidal behaviors while other antipsychotics may lack a specific protective effect: a comprehensive VigiBase study interpreted in the context of the prior literature. Expert Opin Drug Saf. 2024 Sep 11:1-11. doi: 10.1080/14740338.2024.2399094. Epub ahead of print. PMID: 39223773. 20: Takano M, Okada T, Shioda K, Yonekawa C, Suda S. Risperidone suppresses caffeine-induced hyperthermia and hyperactivity in rats. Neurosci Lett. 2024 Sep 25;840:137960. doi: 10.1016/j.neulet.2024.137960. Epub 2024 Sep 1. PMID: 39222834.